Headquartered in Else-krÖner-strasse 1, Bad Homburg Fiscal year ends December NYSE: FMS freseniusmedicalcare.com
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases, serving approximately 4.5 million patients worldwide who regularly undergo dialysis treatment. The company operates through three segments: Care Delivery, which runs a global network of 3,513 dialysis clinics treating approximately 290,000 patients; Value-Based Care, which manages value-based care contracts primarily in the U.S. covering over 154,000 members; and Care Enablement, which manufactures and sells dialysis products including dialysis machines and dialyzers. The company is executing its FME Reignite strategy focused on strengthening core operations, driving profitable growth and innovation, and advancing company culture. A key initiative is the U.S. rollout of the 5008X CAREsystem, an innovative dialysis machine enabling high-volume hemodiafiltration (HVHDF) therapy. The FME25+ transformation program targets EUR 1.2 billion in cumulative savings by end of 2027. Fresenius Medical Care is dual-listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS). Updated
Warren Buffett is the world’s greatest investor. Since becoming chairman of Berkshire Hathaway (NYSE:BRK-A | BRK-A Price Prediction)(NYSE:BRK-B) in the mid-1960’s, he has generated annual average returns of almost 20%, or nearly…
Warren Buffett has obliterated the market’s returns since becoming CEO of Berkshire Hathaway (NYSE:BRK-A | BRK-A Price Prediction)(NYSE:BRK-B) in the mid-1960s. While the S&P 500 has a cumulative return of about 33,000%…
Friday's top analyst upgrades and downgrades included Activision Blizzard, Altria, AppLovin, Bumble, Cano Health, Hanesbrands, Okta, Palo Alto Networks, Redfin, RingCentral, Rivian Automotive, Roblox, Salesforce, SunPower, TJX Companies, Upstart and Viatris.
Tuesday's top analyst upgrades and downgrades included Atlassian, Autodesk, BioMarin Pharmaceutical, Darden Restaurants, DraftKings, eBay, Fortinet, LyondellBasell Industries, Riot Blockchain and WEC Energy.
Here is another look at Gap, Beyond Meat and other stocks that Wall Street analysts expected little from in the past week.
Monday's top analyst upgrades and downgrades included Chewy, Cloudflare, Coca-Cola, Doximity, Ideanomics, GlaxoSmithKline, Micron Technology, SoFi Technologies, Teladoc Health, Twitter and Walmart.
The top analyst upgrades, downgrades and initiations seen on Thursday included Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital and Whiting Petroleum.
The California state Assembly on Wednesday approved a bill that limits the amount dialysis centers can charge patients. The legislation, if passed by the Senate and signed by the governor, may preclude…
The top analyst upgrades, downgrades and initiations seen on Tuesday include Affimed, Coty, Cree, Lululemon Athletica, Myriad Genetics, Tesla and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Friday include Apache, Chesapeake Energy, Goldman Sachs, Intuit, Yum China, Goodyear and Wayfair.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Gold Fields, Humana, Intel, PayPal and Yelp,
Stocks were indicated higher on Thursday, after gains on Tuesday and Wednesday were handy. Oil also crossed back above the $50 barrier again for the first time since October 2015. The notion…
The top analyst calls for Tuesday, January 5, 2016, include Anadarko, CSC, DuPont, First Solar, Halliburton, Mattel, Priceline and Starbucks.
We ran a screen searching for Bank of America Merrill Lynch Buy-rated Japanese and European-listed American depositary shares that have at least 20% of sales in North America.
These are the top analyst upgrades, downgrades and initiations from Wall Street analysts for Tuesday, August 5, 2014. They include Himax Technologies, Ocwen Financial, RetailMeNot and Tenet Healthcare.
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases, serving approximately 4.5 million patients worldwide who regularly undergo dialysis treatment.
24/7 Wall St.'s 12-month price target for FMS is $28.50, rated Buy. The Wall Street consensus target is $24.01. FMS price prediction →
